The link between the SNCA gene and parkinsonism

Neurobiology of Aging

Volumn 36, Issue 3, 2015, Pages 1505-1518

  Xu, Wei ^a   Tan, Lan ^a,b,c   Yu, Jin Tai ^a,b,c  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^b OCEAN UNIVERSITY OF CHINA   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Epigenetics; Genetics; Mechanism; Parkinsonism; SNCA; Therapy

Indexed keywords

ALPHA SYNUCLEIN; SNCA PROTEIN, HUMAN;

3' UNTRANSLATED REGION; AMINO TERMINAL SEQUENCE; BETA SHEET; BINDING SITE; CARBOXY TERMINAL SEQUENCE; COPY NUMBER VARIATION; CPG ISLAND; DISEASE COURSE; DNA METHYLATION; GENE DUPLICATION; GENE FREQUENCY; GENE FUNCTION; GENE LINKAGE DISEQUILIBRIUM; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HUMAN; MISSENSE MUTATION; ONSET AGE; PARKINSONISM; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SNCA GENE; UPREGULATION; GENE EXPRESSION; GENETIC EPIGENESIS; GENETICS; LEWY BODY; MOLECULARLY TARGETED THERAPY; MUTATION; PARKINSONIAN DISORDERS; RISK;

ALPHA-SYNUCLEIN; EPIGENESIS, GENETIC; GENE EXPRESSION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LEWY BODIES; MOLECULAR TARGETED THERAPY; MUTATION; PARKINSONIAN DISORDERS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK;

EID: 84923460328     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.10.042     Document Type: Review

References (146)

1. Ai S.X., Xu Q., Hu Y.C., Song C.Y., Guo J.F., Shen L., Wang C.R., Yu R.L., Yan X.X., Tang B.S. Hypomethylation of SNCA in blood of patients with sporadic Parkinson's disease. J.Neurol. Sci. 2014, 337:123-128.
2. Al-Chalabi A., Durr A., Wood N.W., Parkinson M.H., Camuzat A., Hulot J.S., Morrison K.E., Renton A., Sussmuth S.D., Landwehrmeyer B.G., Ludolph A., Agid Y., Brice A., Leigh P.N., Bensimon G. Genetic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophy. PLoS One 2009, 4:e7114. NNIPPSGeneticStudy Group.
3. Appel-Cresswell S., Vilarino-Guell C., Encarnacion M., Sherman H., Yu I., Shah B., Weir D., Thompson C., Szu-Tu C., Trinh J., Aasly J.O., Rajput A., Rajput A.H., Jon Stoessl A., Farrer M.J. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov. Disord. 2013, 28:811-813.
4. Arduino D.M., Esteves A.R., Cortes L., Silva D.F., Patel B., Grazina M., Swerdlow R.H., Oliveira C.R., Cardoso S.M. Mitochondrial metabolism in Parkinson's disease impairs quality control autophagy by hampering microtubule-dependent traffic. Hum. Mol. Genet. 2012, 21:4680-4702.
5. Barbour R., Kling K., Anderson J.P., Banducci K., Cole T., Diep L., Fox M., Goldstein J.M., Soriano F., Seubert P., Chilcote T.J. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener. Dis. 2008, 5:55-59.
6. Bartels T., Choi J.G., Selkoe D.J. alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 2011, 477:107-110.
7. Bellani S., Sousa V.L., Ronzitti G., Valtorta F., Meldolesi J., Chieregatti E. The regulation of synaptic function by alpha-synuclein. Commun. Integr. Biol. 2010, 3:106-109.
8. Berger S.L. The complex language of chromatin regulation during transcription. Nature 2007, 447:407-412.
9. Blanckenberg J., Bardien S., Glanzmann B., Okubadejo N.U., Carr J.A. The prevalence and genetics of Parkinson's disease in sub-Saharan Africans. J.Neurol. Sci. 2013, 335:22-25.
10. Botta-Orfila T., Ezquerra M., Pastor P., Fernandez-Santiago R., Pont-Sunyer C., Compta Y., Lorenzo-Betancor O., Samaranch L., Marti M.J., Valldeoriola F., Calopa M., Fernandez M., Aguilar M., de Fabregas O., Hernandez-Vara J., Tolosa E. Age at onset in LRRK2-associated PD is modified by SNCA variants. J.Mol. Neurosci. 2012, 48:245-247.
11. Bozi M., Papadimitriou D., Antonellou R., Moraitou M., Maniati M., Vassilatis D.K., Papageorgiou S.G., Leonardos A., Tagaris G., Malamis G., Theofilopoulos D., Kamakari S., Stamboulis E., Hadjigeorgiou G.M., Athanassiadou A., Michelakakis H., Papadimitriou A., Gasser T., Stefanis L. Genetic assessment of familial and early-onset Parkinson's disease in a Greek population. Eur. J. Neurol. 2013, 21:963-968.
12. Brockmann K., Schulte C., Hauser A.K., Lichtner P., Huber H., Maetzler W., Berg D., Gasser T. SNCA: major genetic modifier of age at onset of Parkinson's disease. Mov. Disord. 2013, 28:1217-1221.
13. Burbulla L.F., Kruger R. Converging environmental and genetic pathways in the pathogenesis of Parkinson's disease. J.Neurol. Sci. 2011, 306:1-8.
14. Burre J., Sharma M., Sudhof T.C. Systematic mutagenesis of alpha-synuclein reveals distinct sequence requirements for physiological and pathological activities. J.Neurosci. 2012, 32:15227-15242.
15. Burre J., Sharma M., Tsetsenis T., Buchman V., Etherton M.R., Sudhof T.C. Alpha-synuclein promotes SNARE-complex assembly invivo and invitro. Science 2010, 329:1663-1667.
16. Cabeza-Arvelaiz Y., Fleming S.M., Richter F., Masliah E., Chesselet M.F., Schiestl R.H. Analysis of striatal transcriptome in mice overexpressing human wild-type alpha-synuclein supports synaptic dysfunction and suggests mechanisms of neuroprotection for striatal neurons. Mol. Neurodegener. 2011, 6:83.
17. Cannon J.R., Geghman K.D., Tapias V., Sew T., Dail M.K., Li C., Greenamyre J.T. Expression of human E46K-mutated alpha-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment. Exp. Neurol. 2013, 240:44-56.
18. Cardo L.F., Coto E., de Mena L., Ribacoba R., Lorenzo-Betancor O., Pastor P., Samaranch L., Mata I.F., Diaz M., Moris G., Menendez M., Corao A.I., Alvarez V. Asearch for SNCA 3' UTR variants identified SNP rs356165 as a determinant of disease risk and onset age in Parkinson's disease. J.Mol. Neurosci. 2012, 47:425-430.
19. Cardo L.F., Coto E., de Mena L., Ribacoba R., Mata I.F., Menendez M., Moris G., Alvarez V. Alpha-synuclein transcript isoforms in three different brain regions from Parkinson's disease and healthy subjects in relation to the SNCA rs356165/rs11931074 polymorphisms. Neurosci. Lett. 2014, 562:45-49.
20. Chartier-Harlin M.C., Kachergus J., Roumier C., Mouroux V., Douay X., Lincoln S., Levecque C., Larvor L., Andrieux J., Hulihan M., Waucquier N., Defebvre L., Amouyel P., Farrer M., Destee A. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364:1167-1169.
21. Choi J.M., Woo M.S., Ma H.I., Kang S.Y., Sung Y.H., Yong S.W., Chung S.J., Kim J.S., Shin H.W., Lyoo C.H., Lee P.H., Baik J.S., Kim S.J., Park M.Y., Sohn Y.H., Kim J.H., Kim J.W., Lee M.S., Lee M.C., Kim D.H., Kim Y.J. Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease. Neurogenetics 2008, 9:263-269.
22. Choong C.J., Say Y.H. Neuroprotection of alpha-synuclein under acute and chronic rotenone and maneb treatment is abolished by its familial Parkinson's disease mutations A30P, A53T and E46K. Neurotoxicology 2011, 32:857-863.
23. Choubey V., Safiulina D., Vaarmann A., Cagalinec M., Wareski P., Kuum M., Zharkovsky A., Kaasik A. Mutant A53T alpha-synuclein induces neuronal death by increasing mitochondrial autophagy. J.Biol. Chem. 2011, 286:10814-10824.
24. Chung S.J., Armasu S.M., Anderson K.J., Biernacka J.M., Lesnick T.G., Rider D.N., Cunningham J.M., Ahlskog J.E., Frigerio R., Maraganore D.M. Genetic susceptibility loci, environmental exposures, and Parkinson's disease: a case-control study of gene-environment interactions. Parkinsonism Relat. Disord. 2013, 19:595-599.
25. Chung S.J., Armasu S.M., Biernacka J.M., Lesnick T.G., Rider D.N., Lincoln S.J., Ortolaza A.I., Farrer M.J., Cunningham J.M., Rocca W.A., Maraganore D.M. Common variants in PARK loci and related genes and Parkinson's disease. Mov. Disord. 2011, 26:280-288.
26. Chung S.J., Biernacka J.M., Armasu S.M., Anderson K., Frigerio R., Aasly J.O., Annesi G., Bentivoglio A.R., Brighina L., Chartier-Harlin M.C., Goldwurm S., Hadjigeorgiou G., Jasinska-Myga B., Jeon B.S., Kim Y.J., Kruger R., Lesage S., Markopoulou K., Mellick G., Morrison K.E., Puschmann A., Tan E.K., Crosiers D., Theuns J., Van Broeckhoven C., Wirdefeldt K., Wszolek Z.K., Elbaz A., Maraganore D.M. Alpha-synuclein repeat variants and survival in Parkinson's disease. Mov. Disord. 2014, 29:1053-1057. on behalf of the Genetic Epidemiology of Parkinson's Disease Consortium.
27. Clayton D.F., George J.M. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 1998, 21:249-254.
28. Coelho-Cerqueira E., Carmo-Goncalves P., Pinheiro A.S., Cortines J., Follmer C. alpha-Synuclein as an intrinsically disordered monomer-fact or artefact?. FEBS J. 2013, 280:4915-4927.
29. Cook C., Stetler C., Petrucelli L. Disruption of protein quality control in Parkinson's disease. Cold Spring Harb. Perspect. Med. 2012, 2:a009423.
30. Coppede F. Genetics and epigenetics of Parkinson's disease. ScientificWorldJournal 2012, 2012:489830.
31. Coskuner O., Wise-Scira O. Structures and free energy landscapes of the A53T mutant-type alpha-synuclein protein and impact of A53T mutation on the structures of the wild-type alpha-synuclein protein with dynamics. ACS Chem. Neurosci. 2013, 4:1101-1113.
32. Crews L., Spencer B., Desplats P., Patrick C., Paulino A., Rockenstein E., Hansen L., Adame A., Galasko D., Masliah E. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS One 2010, 5:e9313.
33. Cuervo A.M., Stefanis L., Fredenburg R., Lansbury P.T., Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004, 305:1292-1295.
34. de Boni L., Tierling S., Roeber S., Walter J., Giese A., Kretzschmar H.A. Next-generation sequencing reveals regional differences of the alpha-synuclein methylation state independent of Lewy body disease. Neuromolecular Med. 2011, 13:310-320.
35. Desplats P., Spencer B., Coffee E., Patel P., Michael S., Patrick C., Adame A., Rockenstein E., Masliah E. Alpha-synuclein sequesters Dnmt1 from the nucleus: a novel mechanism for epigenetic alterations in Lewy body diseases. J.Biol. Chem. 2011, 286:9031-9037.
36. Devi L., Raghavendran V., Prabhu B.M., Avadhani N.G., Anandatheerthavarada H.K. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J.Biol. Chem. 2008, 283:9089-9100.
37. Devine M.J., Gwinn K., Singleton A., Hardy J. Parkinson's disease and alpha-synuclein expression. Mov. Disord. 2011, 26:2160-2168.
38. DeWitt D.C., Rhoades E. alpha-Synuclein can inhibit SNARE-mediated vesicle fusion through direct interactions with lipid bilayers. Biochemistry 2013, 52:2385-2387.
39. Diao J., Burre J., Vivona S., Cipriano D.J., Sharma M., Kyoung M., Sudhof T.C., Brunger A.T. Native alpha-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2. Elife 2013, 2:e00592.
40. Doxakis E. Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153. J.Biol. Chem. 2010, 285:12726-12734.
41. Dyllick-Brenzinger M., D'Souza C.A., Dahlmann B., Kloetzel P.M., Tandon A. Reciprocal effects of alpha-synuclein overexpression and proteasome inhibition in neuronal cells and tissue. Neurotox. Res. 2010, 17:215-227.
42. Ebrahimi-Fakhari D., Wahlster L., McLean P.J. Protein degradation pathways in Parkinson's disease: curse or blessing. Acta Neuropathol. 2012, 124:153-172.
43. Eisbach S.E., Outeiro T.F. Alpha-synuclein and intracellular trafficking: impact on the spreading of Parkinson's disease pathology. J.Mol. Med. 2013, 91:693-703.
44. Elliott D.A., Kim W.S., Gorissen S., Halliday G.M., Kwok J.B. Leucine-rich repeat kinase 2 and alternative splicing in Parkinson's disease. Mov. Disord. 2012, 27:1004-1011.
45. Farrer M., Maraganore D.M., Lockhart P., Singleton A., Lesnick T.G., de Andrade M., West A., de Silva R., Hardy J., Hernandez D. alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Hum. Mol. Genet. 2001, 10:1847-1851.
46. Fauvet B., Mbefo M.K., Fares M.B., Desobry C., Michael S., Ardah M.T., Tsika E., Coune P., Prudent M., Lion N., Eliezer D., Moore D.J., Schneider B., Aebischer P., El-Agnaf O.M., Masliah E., Lashuel H.A. alpha-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J.Biol. Chem. 2012, 287:15345-15364.
47. Fujishiro H., Imamura A.Y., Lin W.L., Uchikado H., Mark M.H., Golbe L.I., Markopoulou K., Wszolek Z.K., Dickson D.W. Diversity of pathological features other than Lewy bodies in familial Parkinson's disease due to SNCA mutations. Am. J. Neurodegener. Dis. 2013, 2:266-275.
48. Garraux G., Caberg J.H., Vanbellinghen J.F., Jamar M., Bours V., Moonen G., Dive D. Partial trisomy 4q associated with young-onset dopa-responsive parkinsonism. Arch. Neurol. 2012, 69:398-400.
49. Goldman S.M., Kamel F., Ross G.W., Jewell S.A., Bhudhikanok G.S., Umbach D., Marras C., Hauser R.A., Jankovic J., Factor S.A., Bressman S., Lyons K.E., Meng C., Korell M., Roucoux D.F., Hoppin J.A., Sandler D.P., Langston J.W., Tanner C.M. Head injury, alpha-synuclein Rep1, and Parkinson's disease. Ann. Neurol. 2012, 71:40-48.
50. Gould N., Mor D., Lightfoot R., Malkus K., Giasson B., Ischiropoulos H. Evidence of native alpha-synuclein conformers in the human brain. J.Biol. Chem. 2014, 289:7929-7934.
51. Gui Y.X., Wang X.Y., Kang W.Y., Zhang Y.J., Zhang Y., Zhou Y., Quinn T.J., Liu J., Chen S.D. Extracellular signal-regulated kinase is involved in alpha-synuclein-induced mitochondrial dynamic disorders by regulating dynamin-like protein 1. Neurobiol. Aging 2012, 33:2841-2854.
52. Gurry T., Ullman O., Fisher C.K., Perovic I., Pochapsky T., Stultz C.M. The dynamic structure of alpha-synuclein multimers. J.Am. Chem. Soc. 2013, 135:3865-3872.
53. Halliday G.M., Holton J.L., Revesz T., Dickson D.W. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol. 2011, 122:187-204.
54. Harrison I.F., Dexter D.T. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?. Pharmacol. Ther. 2013, 140:34-52.
55. Heckman M.G., Elbaz A., Soto-Ortolaza A.I., Serie D.J., Aasly J.O., Annesi G., Auburger G., Bacon J.A., Boczarska-Jedynak M., Bozi M., Brighina L., Chartier-Harlin M.C., Dardiotis E., Destee A., Ferrarese C., Ferraris A., Fiske B., Gispert S., Hadjigeorgiou G.M., Hattori N., Ioannidis J.P., Jasinska-Myga B., Jeon B.S., Kim Y.J., Klein C., Kruger R., Kyratzi E., Lin C.H., Lohmann K., Loriot M.A., Lynch T., Mellick G.D., Mutez E., Opala G., Park S.S., Petrucci S., Quattrone A., Sharma M., Silburn P.A., Sohn Y.H., Stefanis L., Tadic V., Tomiyama H., Uitti R.J., Valente E.M., Vassilatis D.K., Vilarino-Guell C., White L.R., Wirdefeldt K., Wszolek Z.K., Wu R.M., Xiromerisiou G., Maraganore D.M., Farrer M.J., Ross O.A. The protective effect of LRRK2p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants. Neurobiol. Aging 2014, 35:266.e5-266.e14. Genetic Epidemiology Of Parkinson's Disease Consortium.
56. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression, and mortality. Neurology 1998, 50:318.
57. Hong D.P., Xiong W., Chang J.Y., Jiang C. The role of the C-terminus of human alpha-synuclein: intra-disulfide bonds between the C-terminus and other regions stabilize non-fibrillar monomeric isomers. FEBS Lett. 2011, 585:561-566.
58. Houlden H., Singleton A.B. The genetics and neuropathology of Parkinson's disease. Acta Neuropathol. 2012, 124:325-338.
59. Hu Y., Tang B., Guo J., Wu X., Sun Q., Shi C., Hu L., Wang C., Wang L., Tan L., Shen L., Yan X., Zhang H. Variant in the 3' region of SNCA associated with Parkinson's disease and serum alpha-synuclein levels. J.Neurol. 2012, 259:497-504.
60. Itokawa K., Sekine T., Funayama M., Tomiyama H., Fukui M., Yamamoto T., Tamura N., Matsuda H., Hattori N., Araki N. Acase of alpha-synuclein gene duplication presenting with head-shaking movements. Mov. Disord. 2013, 28:384-387.
61. Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L., de Silva H.A., Kittel A., Saitoh T. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995, 14:467-475.
62. Janeczek P., Mackay R.K., Lea R.A., Dodd P.R., Lewohl J.M. Reduced expression of alpha-synuclein in alcoholic brain: influence of SNCA-Rep1 genotype. Addict. Biol. 2012, 19:509-515.
63. Jin H., Kanthasamy A., Ghosh A., Yang Y., Anantharam V., Kanthasamy A.G. alpha-Synuclein negatively regulates protein kinase Cdelta expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity. J.Neurosci. 2011, 31:2035-2051.
64. Jowaed A., Schmitt I., Kaut O., Wullner U. Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains. J.Neurosci. 2010, 30:6355-6359.
65. Junn E., Lee K.W., Jeong B.S., Chan T.W., Im J.Y., Mouradian M.M. Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13052-13057.
66. Kalia L.V., Kalia S.K., McLean P.J., Lozano A.M., Lang A.E. alpha-Synuclein oligomers and clinical implications for Parkinson disease. Ann. Neurol. 2013, 73:155-169.
67. Kasten M., Klein C. The many faces of alpha-synuclein mutations. Mov. Disord. 2013, 28:697-701.
68. Keri S., Nagy H., Myers C.E., Benedek G., Shohamy D., Gluck M.A. Risk and protective haplotypes of the alpha-synuclein gene associated with Parkinson's disease differentially affect cognitive sequence learning. Genes Brain Behav. 2008, 7:31-36.
69. Khodr C.E., Becerra A., Han Y., Bohn M.C. Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects. Brain Res. 2014, 1550:47-60.
70. Khodr C.E., Pedapati J., Han Y., Bohn M.C. Inclusion of a portion of the native SNCA 3'UTR reduces toxicity of human S129A SNCA on striatal-projecting dopamine neurons in rat substantia nigra. Dev. Neurobiol. 2012, 72:906-917.
71. Khodr C.E., Sapru M.K., Pedapati J., Han Y., West N.C., Kells A.P., Bankiewicz K.S., Bohn M.C. An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons. Brain Res. 2011, 1395:94-107.
72. Kiely A.P., Asi Y.T., Kara E., Limousin P., Ling H., Lewis P., Proukakis C., Quinn N., Lees A.J., Hardy J., Revesz T., Houlden H., Holton J.L. alpha-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy?. Acta Neuropathol. 2013, 125:753-769.
73. Kim H.J., Jeon B.S., Yoon M.Y., Park S.S., Lee K.W. Increased expression of alpha-synuclein by SNCA duplication is associated with resistance to toxic stimuli. J.Mol. Neurosci. 2012, 47:249-255.
74. Kim H.J., Park G., Jeon B.S., Park W.Y., Kim Y.E. Amir-153 binding site variation in SNCA in a patient with Parkinson's disease. Mov. Disord. 2013, 28:1755-1756.
75. Kim S.R., Ries V., Cheng H.C., Kareva T., Oo T.F., Yu W.H., Duff K., Kholodilov N., Burke R.E. Age and alpha-synuclein expression interact to reveal a dependence of dopaminergic axons on endogenous Akt/PKB signaling. Neurobiol. Dis. 2011, 44:215-222.
76. Kim S.S., Moon K.R., Choi H.J. Interference of alpha-synuclein with cAMP/PKA-dependent CREB signaling for tyrosine hydroxylase gene expression in SK-N-BE(2)C cells. Arch. Pharm. Res. 2011, 34:837-845.
77. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 1998, 18:106-108.
78. Kurz A., May C., Schmidt O., Muller T., Stephan C., Meyer H.E., Gispert S., Auburger G., Marcus K. A53T-alpha-synuclein-overexpression in the mouse nigrostriatal pathway leads to early increase of 14-3-3 epsilon and late increase of GFAP. J.Neural Transm. 2012, 119:297-312.
79. Lee H.J., Kang S.J., Lee K., Im H. Human alpha-synuclein modulates vesicle trafficking through its interaction with prenylated Rab acceptor protein 1. Biochem. Biophys. Res. Commun. 2011, 412:526-531.
80. Lemkau L.R., Comellas G., Kloepper K.D., Woods W.S., George J.M., Rienstra C.M. Mutant protein A30P alpha-synuclein adopts wild-type fibril structure, despite slower fibrillation kinetics. J.Biol. Chem. 2012, 287:11526-11532.
81. Lesage S., Anheim M., Letournel F., Bousset L., Honore A., Rozas N., Pieri L., Madiona K., Durr A., Melki R., Verny C., Brice A. G51D alpha-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann. Neurol. 2013, 73:459-471. for the French Parkinson's Disease Genetics Study Group.
82. Li N.N., Mao X.Y., Chang X.L., Zhao D.M., Zhang J.H., Liao Q., Yu W.J., Tan E.K., Peng R. SNCA rs356219 variant increases risk of sporadic Parkinson's disease in ethnic Chinese. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2013, 162B:452-456.
83. Lim Y., Kehm V.M., Lee E.B., Soper J.H., Li C., Trojanowski J.Q., Lee V.M. alpha-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies. J.Neurosci. 2011, 31:10076-10087.
84. Lin X., Parisiadou L., Sgobio C., Liu G., Yu J., Sun L., Shim H., Gu X.L., Luo J., Long C.X., Ding J., Mateo Y., Sullivan P.H., Wu L.G., Goldstein D.S., Lovinger D., Cai H. Conditional expression of Parkinson's disease-related mutant alpha-synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1. J.Neurosci. 2012, 32:9248-9264.
85. Malkus K.A., Ischiropoulos H. Regional deficiencies in chaperone-mediated autophagy underlie alpha-synuclein aggregation and neurodegeneration. Neurobiol. Dis. 2012, 46:732-744.
86. Massano J., Bhatia K.P. Clinical approach to Parkinson's disease: features, diagnosis, and principles of management. Cold Spring Harb. Perspect. Med. 2012, 2:a008870.
87. Matsumoto L., Takuma H., Tamaoka A., Kurisaki H., Date H., Tsuji S., Iwata A. CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease. PLoS One 2010, 5:e15522.
88. McLean J.R., Hallett P.J., Cooper O., Stanley M., Isacson O. Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression. Mol. Cell. Neurosci. 2012, 49:230-239.
89. Meeus B., Verstraeten A., Crosiers D., Engelborghs S., Van den Broeck M., Mattheijssens M., Peeters K., Corsmit E., Elinck E., Pickut B., Vandenberghe R., Cras P., De Deyn P.P., Van Broeckhoven C., Theuns J. DLB and PDD: a role for mutations in dementia and Parkinson disease genes?. Neurobiol. Aging 2012, 33:629.e5-629.e18.
90. Michell A.W., Luheshi L.M., Barker R.A. Skin and plateletalpha-synuclein as peripheral biomarkers of Parkinson's disease. Neurosci. Lett. 2005, 381:294-298.
91. Mollenhauer B., Trautmann E., Otte B., Ng J., Spreer A., Lange P., Sixel-Doring F., Hakimi M., Vonsattel J.P., Nussbaum R., Trenkwalder C., Schlossmacher M.G. alpha-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system. J.Neural Transm. 2012, 119:739-746.
92. Mouradian M.M. MicroRNAs in Parkinson's disease. Neurobiol. Dis. 2012, 46:279-284.
93. Mullin S., Schapira A. alpha-Synuclein and mitochondrial dysfunction in Parkinson's disease. Mol. Neurobiol. 2013, 47:587-597.
94. Musgrove R.E., King A.E., Dickson T.C. alpha-Synuclein protects neurons from apoptosis downstream of free-radical production through modulation of the MAPK signalling pathway. Neurotox. Res. 2013, 23:358-369.
95. Myhre R., Toft M., Kachergus J., Hulihan M.M., Aasly J.O., Klungland H., Farrer M.J. Multiple alpha-synuclein gene polymorphisms are associated with Parkinson's disease in a Norwegian population. Acta Neurol. Scand. 2008, 118:320-327.
96. Nishioka K., Ross O.A., Ishii K., Kachergus J.M., Ishiwata K., Kitagawa M., Kono S., Obi T., Mizoguchi K., Inoue Y., Imai H., Takanashi M., Mizuno Y., Farrer M.J., Hattori N. Expanding the clinical phenotype of SNCA duplication carriers. Mov. Disord. 2009, 24:1811-1819.
97. Nuscher B., Kamp F., Mehnert T., Odoy S., Haass C., Kahle P.J., Beyer K. Alpha-synuclein has a high affinity for packing defects in a bilayer membrane: a thermodynamics study. J.Biol. Chem. 2004, 279:21966-21975.
98. Oaks A.W., Frankfurt M., Finkelstein D.I., Sidhu A. Age-dependent effects of A53T alpha-synuclein on behavior and dopaminergic function. PLoS One 2013, 8:e60378.
99. Ozansoy M., Basak A.N. The central theme of Parkinson's disease: alpha-synuclein. Mol. Neurobiol. 2013, 47:460-465.
100. Paillusson S., Clairembault T., Biraud M., Neunlist M., Derkinderen P. Activity-dependent secretion of alpha-synuclein by enteric neurons. J.Neurochem. 2013, 125:512-517.
101. Parsian A.J., Racette B.A., Zhao J.H., Sinha R., Patra B., Perlmutter J.S., Parsian A. Association of alpha-synuclein gene haplotypes with Parkinson's disease. Parkinsonism Relat. Disord. 2007, 13:343-347.
102. Peeraully T., Tan E.K. Genetic variants in sporadic Parkinson's disease: east vs west. Parkinsonism Relat. Disord. 2012, 18(Suppl 1):S63-S65.
103. Pihlstrom L., Toft M. Genetic variability in SNCA and Parkinson's disease. Neurogenetics 2011, 12:283-293.
104. Platt N.J., Gispert S., Auburger G., Cragg S.J. Striatal dopamine transmission is subtly modified in human A53Talpha-synuclein overexpressing mice. PLoS One 2012, 7:e36397.
105. Plotegher N., Gratton E., Bubacco L. Number and brightness analysis of alpha-synuclein oligomerization and the associated mitochondrial morphology alterations in live cells. Biochim. Biophys. Acta 2014, 1840:2014-2024.
106. Polymeropoulos M.H., Higgins J.J., Golbe L.I., Johnson W.G., Ide S.E., Di Iorio G., Sanges G., Stenroos E.S., Pho L.T., Schaffer A.A., Lazzarini A.M., Nussbaum R.L., Duvoisin R.C. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 1996, 274:1197-1199.
107. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
108. Puschmann A. Monogenic Parkinson's disease and parkinsonism: clinical phenotypes and frequencies of known mutations. Parkinsonism Relat. Disord. 2013, 19:407-415.
109. Ritz B., Rhodes S.L., Bordelon Y., Bronstein J. alpha-Synuclein genetic variants predict faster motor symptom progression in idiopathic Parkinson disease. PLoS One 2012, 7:e36199.
110. Ross O.A., Vilarino-Guell C., Wszolek Z.K., Farrer M.J., Dickson D.W. Reply to: SNCA variants are associated with increased risk of multiple system atrophy. Ann. Neurol. 2010, 67:414-415.
111. Sarafian T.A., Ryan C.M., Souda P., Masliah E., Kar U.K., Vinters H.V., Mathern G.W., Faull K.F., Whitelegge J.P., Watson J.B. Impairment of mitochondria in adult mouse brain overexpressing predominantly full-length, N-terminally acetylated human alpha-synuclein. PLoS One 2013, 8:e63557.
112. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J.Neurochem. 1990, 54:823-827.
113. Schmitt I., Wullner U., van Rooyen J.P., Khazneh H., Becker J., Volk A., Kubisch C., Becker T., Kostic V.S., Klein C., Ramirez A. Variants in the 3'UTR of SNCA do not affect miRNA-433 binding and alpha-synuclein expression. Eur. J. Hum. Genet. 2012, 20:1265-1269.
114. Scholz S.W., Houlden H., Schulte C., Sharma M., Li A., Berg D., Melchers A., Paudel R., Gibbs J.R., Simon-Sanchez J., Paisan-Ruiz C., Bras J., Ding J., Chen H., Traynor B.J., Arepalli S., Zonozi R.R., Revesz T., Holton J., Wood N., Lees A., Oertel W., Wullner U., Goldwurm S., Pellecchia M.T., Illig T., Riess O., Fernandez H.H., Rodriguez R.L., Okun M.S., Poewe W., Wenning G.K., Hardy J.A., Singleton A.B., Del Sorbo F., Schneider S., Bhatia K.P., Gasser T. SNCA variants are associated with increased risk for multiple system atrophy. Ann. Neurol. 2009, 65:610-614.
115. Seidel K., Schols L., Nuber S., Petrasch-Parwez E., Gierga K., Wszolek Z., Dickson D., Gai W.P., Bornemann A., Riess O., Rami A., Den Dunnen W.F., Deller T., Rub U., Kruger R. First appraisal of brain pathology owing to A30P mutant alpha-synuclein. Ann. Neurol. 2010, 67:684-689.
116. Selkoe D., Dettmer U., Luth E., Kim N., Newman A., Bartels T. Defining the native state of alpha-synuclein. Neurodegener. Dis. 2014, 13:114-117.
117. Sharma M., Ioannidis J.P., Aasly J.O., Annesi G., Brice A., Van Broeckhoven C., Bertram L., Bozi M., Crosiers D., Clarke C., Facheris M., Farrer M., Garraux G., Gispert S., Auburger G., Vilarino-Guell C., Hadjigeorgiou G.M., Hicks A.A., Hattori N., Jeon B., Lesage S., Lill C.M., Lin J.J., Lynch T., Lichtner P., Lang A.E., Mok V., Jasinska-Myga B., Mellick G.D., Morrison K.E., Opala G., Pramstaller P.P., Pichler I., Park S.S., Quattrone A., Rogaeva E., Ross O.A., Stefanis L., Stockton J.D., Satake W., Silburn P.A., Theuns J., Tan E.K., Toda T., Tomiyama H., Uitti R.J., Wirdefeldt K., Wszolek Z., Xiromerisiou G., Yueh K.C., Zhao Y., Gasser T., Maraganore D., Kruger R. Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology 2012, 79:659-667. GEO-PD Consortium.
118. Shulman J.M., Yu L., Buchman A.S., Evans D.A., Schneider J.A., Bennett D.A., De Jager P.L. Association of Parkinson disease risk loci with mild parkinsonian signs in older persons. JAMA Neurol. 2014, 71:429-435.
119. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., Gwinn-Hardy K. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
120. Song J.X., Lu J.H., Liu L.F., Chen L.L., Durairajan S.S., Yue Z., Zhang H.Q., Li M. HMGB1 is involved in autophagy inhibition caused by SNCA/alpha-synuclein overexpression: a process modulated by the natural autophagy inducer corynoxine B. Autophagy 2014, 10:144-154.
121. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
122. St Laurent R., O'Brien L.M., Ahmad S.T. Sodium butyrate improves locomotor impairment and early mortality in a rotenone-induced Drosophila model of Parkinson's disease. Neuroscience 2013, 246:382-390.
123. Stemberger S., Scholz S.W., Singleton A.B., Wenning G.K. Genetic players in multiple system atrophy: unfolding the nature of the beast. Neurobiol. Aging 2011, 32:1924.e5-1924.e14.
124. Szamosi A., Nagy H., Keri S. Delay discounting of reward and caudate nucleus volume in individuals with alpha-synuclein gene duplication before and after the development of Parkinson's disease. Neurodegener. Dis. 2013, 11:72-78.
125. Tan C.C., Yu J.T., Tan M.S., Jiang T., Zhu X.C., Tan L. Autophagy in aging and neurodegenerative diseases: implications for pathogenesis and therapy. Neurobiol. Aging 2014, 35:941-957.
126. Tan E.K., Tan C., Shen H., Chai A., Lum S.Y., Teoh M.L., Yih Y., Wong M.C., Zhao Y. Alpha synuclein promoter and risk of Parkinson's disease: microsatellite and allelic size variability. Neurosci. Lett. 2003, 336:70-72.
127. Tan Y.Y., Wu L., Zhao Z.B., Wang Y., Xiao Q., Liu J., Wang G., Ma J.F., Chen S.D. Methylation of alpha-synuclein and leucine-rich repeat kinase 2 in leukocyte DNA of Parkinson's disease patients. Parkinsonism Relat. Disord. 2014, 20:308-313.
128. Taylor T.N., Potgieter D., Anwar S., Senior S.L., Janezic S., Threlfell S., Ryan B., Parkkinen L., Deltheil T., Cioroch M., Livieratos A., Oliver P.L., Jennings K.A., Davies K.E., Ansorge O., Bannerman D.M., Cragg S.J., Wade-Martins R. Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P alpha-synuclein BAC transgenic mouse. Neurobiol. Dis. 2014, 62:193-207.
129. Tokutake T., Ishikawa A., Yoshimura N., Miyashita A., Kuwano R., Nishizawa M., Ikeuchi T. Clinical and neuroimaging features of patient with early-onset Parkinson's disease with dementia carrying SNCA p.G51D mutation. Parkinsonism Relat. Disord. 2014, 20:262-264.
130. Tozzi A., Costa C., Siliquini S., Tantucci M., Picconi B., Kurz A., Gispert S., Auburger G., Calabresi P. Mechanisms underlying altered striatal synaptic plasticity in old A53T-alpha synuclein overexpressing mice. Neurobiol. Aging 2012, 33:1792-1799.
131. Tsuboi Y. Environmental-genetic interactions in the pathogenesis of Parkinson's disease. Exp. Neurobiol. 2012, 21:123-128.
132. UK Parkinson's Disease Consortium, Wellcome Trust Case Control Consortium, Spencer C.C., Plagnol V., Strange A., Gardner M., Paisan-Ruiz C., Band G., Barker R.A., Bellenguez C., Bhatia K., Blackburn H., Blackwell J.M., Bramon E., Brown M.A., Brown M.A., Burn D., Casas J.P., Chinnery P.F., Clarke C.E., Corvin A., Craddock N., Deloukas P., Edkins S., Evans J., Freeman C., Gray E., Hardy J., Hudson G., Hunt S., Jankowski J., Langford C., Lees A.J., Markus H.S., Mathew C.G., McCarthy M.I., Morrison K.E., Palmer C.N., Pearson J.P., Peltonen L., Pirinen M., Plomin R., Potter S., Rautanen A., Sawcer S.J., Su Z., Trembath R.C., Viswanathan A.C., Williams N.W., Morris H.R., Donnelly P., Wood N.W. Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Hum. Mol. Genet. 2011, 20:345-353.
133. van der Vegt J.P., van Nuenen B.F., Bloem B.R., Klein C., Siebner H.R. Imaging the impact of genes on Parkinson's disease. Neuroscience 2009, 164:191-204.
134. Vishwanathan Padmaja M., Jayaraman M., Srinivasan A.V., Srikumari Srisailapathy C.R., Ramesh A. The SNCA (A53T, A30P, E46K) and LRRK2 (G2019S) mutations are rare cause of Parkinson's disease in South Indian patients. Parkinsonism Relat. Disord. 2012, 18:801-802.
135. Wang N., Gibbons C.H., Lafo J., Freeman R. alpha-Synuclein in cutaneous autonomic nerves. Neurology 2013, 81:1604-1610.
136. Wang W., Perovic I., Chittuluru J., Kaganovich A., Nguyen L.T., Liao J., Auclair J.R., Johnson D., Landeru A., Simorellis A.K., Ju S., Cookson M.R., Asturias F.J., Agar J.N., Webb B.N., Kang C., Ringe D., Petsko G.A., Pochapsky T.C., Hoang Q.Q. Asoluble alpha-synuclein construct forms a dynamic tetramer. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:17797-17802.
137. Wang X.Y., Kang W.Y., Yang Q., Zhang L.Y., Chen S.D., Liu J. Using gastrocnemius sEMG and plasma alpha-synuclein for the prediction of freezing of gait in Parkinson's disease patients. PLoS One 2014, 9:e89353.
138. Wider C., Ross O.A., Nishioka K., Heckman M.G., Vilarino-Guell C., Jasinska-Myga B., Erketin-Taner N., Rademakers R., Graff-Radford N.R., Mash D.C., Papapetropoulos S., Duara R., Uchikado H., Wszolek Z.K., Farrer M.J., Dickson D.W. An evaluation of the impact of MAPT, SNCA and APOE on the burden of Alzheimer's and Lewy body pathology. J.Neurol. Neurosurg. Psychiatry 2012, 83:424-429.
139. Winslow A.R., Chen C.W., Corrochano S., Acevedo-Arozena A., Gordon D.E., Peden A.A., Lichtenberg M., Menzies F.M., Ravikumar B., Imarisio S., Brown S., O'Kane C.J., Rubinsztein D.C. alpha-Synuclein impairs macroautophagy: implications for Parkinson's disease. J.Cel. Biol. 2010, 190:1023-1037.
140. Winslow A.R., Rubinsztein D.C. The Parkinson disease protein alpha-synuclein inhibits autophagy. Autophagy 2011, 7:429-431.
141. Witt S.N. Molecular chaperones, alpha-synuclein, and neurodegeneration. Mol. Neurobiol. 2013, 47:552-560.
142. Wong G., Nass R. miRNAs and their putative roles in the development and progression of Parkinson's disease. Front. Genet. 2012, 3:315.
143. Yonova-Doing E., Atadzhanov M., Quadri M., Kelly P., Shawa N., Musonda S.T., Simons E.J., Breedveld G.J., Oostra B.A., Bonifati V. Analysis of LRRK2, SNCA, Parkin, PINK1, and DJ-1 in Zambian patients with Parkinson's disease. Parkinsonism Relat. Disord. 2012, 18:567-571.
144. Yu W.H., Dorado B., Figueroa H.Y., Wang L., Planel E., Cookson M.R., Clark L.N., Duff K.E. Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein. Am. J. Pathol. 2009, 175:736-747.
145. Yun J.Y., Lee W.W., Lee J.Y., Kim H.J., Park S.S., Jeon B.S. SNCA variants and multiple system atrophy. Ann. Neurol. 2010, 67:554-555.
146. Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atares B., Llorens V., Gomez Tortosa E., del Ser T., Munoz D.G., de Yebenes J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55:164-173.